Rash News and Research

RSS

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Man dies from flesh-eating disease

A rare flesh-eating disease has claimed the life of a man in Britain. The 60 year old man Tony Williamson died days after a flesh-eating disease spread through his body from a small cut on the inside of his right arm.

28 Dec 2008

Dengue fever outbreak spreading across Cairns

An outbreak of dengue fever in Cairns, in far north Queensland, continues to cause alarm as the number now affected has reportedly reached 50 and appears to be rising.

22 Dec 2008

FDA approves Gleevec (imatinib mesylate) to prevent gastrointestinal stromal tumor

The U.S. Food and Drug Administration has approved Gleevec (imatinib mesylate) for a new indication – keeping cancer from growing in patients following surgical removal of a gastrointestinal stromal tumor or GIST.

21 Dec 2008

Patients with skin disease psoriasis need evaluation of coronary artery disease risk

According to new recommendations in the December 10 issue of The American Journal of Cardiology (AJC), published by Elsevier, new research is called for and patients with severe forms of the skin disease psoriasis should receive evaluation and possible treatment to reduce their risk of coronary artery disease (CAD).

18 Dec 2008

Scientists coax bright white light from zinc oxide

Duke University and United States Army scientists have found that a cheap and nontoxic sunburn and diaper rash preventative can be made to produce brilliant light best suited to the human eye.

18 Dec 2008

Psoriasis sufferers more likely to have higher levels of leptin

Patients with the skin disease psoriasis appear more likely to have higher levels of leptin (a hormone produced by fat cells that may contribute to obesity and other metabolic abnormalities) than persons without psoriasis, according to a report in the December issue of Archives of Dermatology.

15 Dec 2008

3.6 million Americans living with active, undiagnosed psoriasis, unaware of associated risks

Armed with research concluding that psoriasis is associated with an increased risk of heart attacks and other cardiovascular conditions, Joel M. Gelfand, MD, MSCE, Assistant Professor of Dermatology at the University of Pennsylvania School of Medicine and colleagues released an editorial consensus in the American Journal of Cardiology today¸ calling for psoriasis patients to be educated about and screened for cardiovascular risk factors.

15 Dec 2008

Novel therapeutic approaches for various forms of thrombocytopenia

Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

FDA advisory committee to dscuss PMA for Genzyme's Synvisc-One

Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland.

8 Dec 2008

Reactions to HPV vaccine Gardasil rare

Research by Australian scientists has found that adverse reactions to the HPV vaccine Gardasil are rare and most schoolgirls are able to tolerate subsequent doses.

3 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

Schoolies warned that after-effects of drinking or drug-taking could disguise the start of meningococcal disease

Following reports that an 18-year-old student celebrating 'schoolies' week on Queensland's Gold Coast has been hospitalised with meningococcal disease, health officials have warned schoolies that the after-effects of drinking or drug-taking could disguise the onset of the disease.

26 Nov 2008

Selzentry (maraviroc) becomes fully approved HIV antiretrovial

The U.S. Food and Drug Administration (FDA) has granted Selzentry (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals.

25 Nov 2008

Seniors are feeling anxious

For older adults who have lived through the Great Depression, news stories comparing present circumstances to the harsh realities of food lines, few jobs, and extreme poverty of the 1930's may be panic-producing.

25 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

10 symptoms that should never be ignored

Not every ache and pain merits a quick trip to the doctor -- but some do.

6 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

New strategy to treat human infections caused by the yeast Candida albicans

Researchers at Georgetown University Medical Center (GUMC) have successfully tested a genetic strategy designed to improve treatment of human infections caused by the yeast Candida albicans, ranging from diaper rash, vaginitis, oral infections (or thrush which is common in HIV/AIDS patients), as well as invasive, blood-borne and life-threatening diseases.

27 Oct 2008

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.

22 Oct 2008